Balancing the Burden of Treatment for nAMD and DME Through Innovative Therapeutics and Surgical Delivery Systems: Are We Losing Sight of Emerging Options?

1.25 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Physician in White Coat


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Activity Description

Novel delivery systems, gene therapy, as well as agents with unique mechanisms of action that extend dosing frequency, are being assessed in clinical studies for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These innovative approaches aim to address the unmet needs of treatment burden and suboptimal treatment responses often seen in patients with retinal diseases. Unlike intravitreal injections, several of these new therapeutic modalities require specific surgical approaches that must be utilized to provide optimal outcomes and safety. In this CME activity, experts in the field will evaluate the latest efficacy and safety data for novel delivery systems and therapies with unique mechanisms of action that have the potential to lengthen the interval between treatments for nAMD and DME, as well as discuss best practices and procedures that can reduce complications with new therapeutic modalities that require unique surgical approaches.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration or diabetic macular edema.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Recognize the current need for treatments that reduce the burden of frequent anti-VEGF injections for the management of neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
  • Summarize new evidence about novel delivery systems that may reduce the need for frequent anti-VEGF injections in patients with nAMD or DME.
  • Outline emerging therapeutics with unique mechanisms of action that can lengthen the time between treatments for patients with nAMD or DME.
  • Describe surgical techniques and best practices that can reduce the potential for complications when implanting and refilling the port delivery system with ranibizumab.

Activity Chair

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV


Caroline Baumal, MD
Professor of Ophthalmology
New England Eye Center
Tufts University School of Medicine
Boston, MA

Carl D. Regillo, MD, FACS
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, January 7, 2022, to January 6, 2023.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Arshad M. Khanani, MD, MA
Consultant: Adverum, Aerpio, Allergan, Apellis, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, Kodiak, Novartis, Opthea, Oxurion, Regenxbio, Surrozen
Speaker for Ineligible Company: Allergan, Genentech, Novartis
Independent Research Contractor: Adverum, Alkahest, Allegro, Allergan, Annexon, Gemini, Genentech, Gyroscope, Iveric Bio, Kodiak, NGM Pharmaceuticals, Novartis, Opthea, Ophthotech, Oxurion, Regenxbio

Caroline Baumal, MD
Consultant: Gemini, Genentech, Novartis, Zeiss

Carl D. Regillo, MD, FACS
Consultant: Adverum, Allergan, Annexon, Chengdu Kanghong, EyePoint, Iveric Bio, Kodiak, Lineage, Merck, NGM, Notal, Novartis, Ocugen, Opthea, Stealth, Thea, Zeiss
Independent Research Contractor:Adverum, Allergan, Annexon, Astellas, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric Bio, Kodiak, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, Regenxbio
Individual Stocks & Stock Options: Iveric Bio

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at